News Archive
Oncolytics Biotech Inc. ("Oncolytics") today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers.
Scientists have wrestled to understand why Huntington's disease, which is caused by a single gene mutation, can produce such variable symptoms. An authoritative review by a group of leading experts summarizes the progress relating cell loss in the striatum and cerebral cortex to symptom profile in Huntington's disease, suggesting a possible direction for developing targeted therapies.
Researchers at The Scripps Research Institute are reporting the results of a recent study that addresses why different tissues in the human body vary in their susceptibility to "amyloid" diseases, which include Alzheimer's disease and a cluster of ailments called the familial amyloidoses.
Stem cell research laboratories at the University of California, Riverside, Loma Linda University and the California State University at San Bernardino have formed the "Inland Empire Stem Cell Consortium" to enhance collaboration among the three universities and bring focus to stem cell work being done in inland Southern California.
› Verified 9 days ago